OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 101 - 110 of 698 studies

Neurological Oral and Gastrointestinal

A Prospective, Observational Cohort Study to Assess Long-Term Safety in Patients Prescribed Epidyolex® with a Focus on Drug-induced Liver Injury (DILI)

This is a multicentre, prospective, non-interventional observational cohort study of patients who are planned to receive, or already receiving Epidyolex under real-world conditions of clinical care. This study is designed to address a Pharmacovigilance Risk Assessment Committee (PRAC) request to conduct a Category 3 Post-Authorisation Safety Study (PASS), as requested in the Risk Management Plan (RMP) at the time of approval. While 12 safety concerns were noted in the RMP, PRAC emphasis was on the need to further characterize the ...

GO TO STUDY Go

Neurological

Characterisation of a panel of disease biomarkers in peripheral blood from individuals with amyotrophic lateral sclerosis/motor neuron disease

This study will evaluate the expression of neurofilaments and of other relevant molecules in blood samples taken from individuals with amyotrophic lateral sclerosis at different time points during the development of the disease. Our aim is to validate easily accessible disease biomarkers functioning as reliable predictors of disease severity and capable of providing information about the stratification of the disease phenotypes. Control groups will include healthy individuals and patients with a compressive radiculopathy. Recruitment will take place in 4 motor ...

GO TO STUDY Go

Reproductive health and childbirth

A phase III, multi-centre, randomised placebo-controlled trial of oral iron supplementation for the prevention of maternal anaemia

The study hypothesis is that a strategy of universal primary prevention of anaemia during pregnancy with oral iron supplementation will impact the composite primary outcome of pre-term birth,stillbirth,neonatal death and small for gestational age (SGA).

GO TO STUDY Go

Cancer and neoplasms

Response Adapted incorporation of Tislelizumab into the Front-line treatment of older patients with Hodgkin lYmphoma (RATIFY)

RATiFY is a non-randomised,multicentre,phase II trial. Eighty patients will be recruited and,following initial treatment with 3 cycles of tislelizumab and PET-CT with ceCT scan,will be assigned to 1 of 5 treatment groups (Groups A to E) based on disease stage,risk,and response. Patients with early stage lymphoma showing good response (Group A) will receive radiotherapy and further tislelizumab for up to 2 years,but no chemotherapy. All other patients (Groups B-E) will receive further tislelizumab with AVD chemotherapy for between 2 and ...

GO TO STUDY Go

Renal and Urogenital Skin

Proactive against reactive therapy for the prevention of lichen sclerosus exacerbation and progression of disease – a pragmatic, parallel group randomised controlled trial with embedded economic evaluation and process evaluation (PEARLS)

PEARLS is a 2-arm,parallel-group,individually randomised,open label assessor-blinded,multicentre,superiority trial with an internal pilot phase. It is a pragmatic trial and the trial participants in both intervention and comparator group will receive commonly prescribed topical corticosteroids (TCSs),which is tailored for the participant. The only difference between the treatment groups is the treatment regimen/strategy. There are number of TCS products available on the market and all available brands and forms can be prescribed to participants. Participants will be randomised to one of ...

GO TO STUDY Go

Oral and Gastrointestinal

Accelerating Discovery: Actionable NASH Cirrhosis Endpoints (ADVANCE)

ADVANCE is a longitudinal cohort study supporting scientific research by members of the 'NASH Disease Translational Accelerator' (NASH-DTA) Consortium. The overarching aim is to leverage a greater understanding of disease pathophysiology to develop robust methods for diagnosis, risk stratification and therapy for patients with Non-Alcoholic Fatty Liver Disease related advanced liver fibrosis/cirrhosis (“compensated advanced chronic liver disease, cACLD”). To achieve this we will assemble a longitudinal observational cohort of well-characterised patients with Non-Alcoholic Fatty Liver Disease (NAFLD) related advanced liver ...

GO TO STUDY Go

Neurological

Ambroxol to Slow Progression in Parkinson Disease (ASPro-PD): A Phase IIIA multi-centre randomised placebo-controlled trial

This is a phase IIIa,multi-centre,randomised,doubled-blind,parallel-group,placebo-controlled trial,with a 104-week blinded treatment period followed by a 26-week open-label extension. The aim of the trial is to assess whether 1260mg of ambroxol daily can slow down the progression of Parkinson’s disease (PD),in comparison to a matching placebo,and to establish the safety of long-term use of ambroxol at this dose. 330 participants will be recruited from approximately 10 UK sites over a 24-month period. Data analysis will be performed by UCL CCTU’s statisticians at ...

GO TO STUDY Go

Oral and Gastrointestinal

Double-blind randomised controlled trial for treatment of Gastro-Oesophageal reflux disease; LINX management system vs. Fundoplication (GOLF)

Reflux disease can severely impact upon quality-of-life and lead to complications, including ulceration of the oesophagus. It is often controlled with self-help measures and medication. However, sometimes surgery is recommended. The current standard surgical treatment is called a fundoplication. This operation is carried out through keyhole (laparoscopic) surgery, and tightens the lower oesophagus to prevent reflux. Fundoplication is very safe and improves the quality-of-life of most patients. However, many patients have gas bloating, difficulty swallowing and recurrence of their reflux ...

GO TO STUDY Go

Infection Inflammatory and immune system

Investigating the impact of the pulmonary Innate Immune Response and microbiome after exposure to Mycobacterium Tuberculosis

Tuberculosis (TB) kills more people than any other single infectious disease. We really need an effective vaccine to prevent people getting TB, but we don’t understand what sort of immune response is needed to protect people. The very early responses in TB infection, is not well understood, partly because it is difficult to study as most of the changes happen before people get symptoms. This study has been designed to help to answer two key questions about the early immune ...

GO TO STUDY Go

Cancer and neoplasms

A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agent(s) in Participants With Relapsed/Refractory Haematologic Malignancies (PRIMAVERA)

This is a FTiH modular, Phase I/II, open-label, multicentre, dose escalation and expansion study in participants with r/r haematologic malignancies. The study consists of several study modules, each evaluating the safety, tolerability, PK, pharmacodynamics, and efficacy of orally administered AZD3470 as monotherapy and in combination with other anticancer agents. This study will follow a modular protocol design evaluating AZD3470 as monotherapy and in combination with other anticancer agents. New cohorts (including further monotherapy expansion) and new modules for combination treatments may be ...

GO TO STUDY Go